Keytruda’s latest FDA nod could give Merck a blockbuster edge in kidney cancer, as the PD-1 inhibitor on Nov. 18 became the first immunotherapy approved to treat early renal cell carcinoma at intermediate-high or high risk of recurrence. Renal cell carcinoma is the most common form of kidney cancer. Keytruda, in combination with Pfizer’s Inlyta, was initially approved as a first-line treatment for kidney cancer in August 2019. It holds covered or better status for 83% of all insured lives under the medical benefit, compared to 71% under the pharmacy benefit.
SOURCE: MMIT Analytics, as of 11/22/21